OncoDaily· @oncodaily · X·· 14 小时前评分70
正文 · 原文
Oncologists Discuss NATALEE Trial
The six-year #NATALEE trial results presented at #ESMO2026 showed an overall survival benefit and sustained improvements in invasive disease-free survival with adjuvant ribociclib plus endocrine therapy in patients with HR+/HER2− early breast cancer.
https://oncodaily.com/science/natalee-esmo-26-615553
@KefahMokbel @SuyogCancer @emadshash @Timothee_MD @DrBarbiOnc @HundalJasmin @Aydah_AlAwadhi @DrSGraff @dr_yakupergun @kazuki_nozawa @sara_soliman7 @stolaney1 @Dr_Oncologista @DrHBurstein
49 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org来源：OncoDaily · x.com